We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
2MRC Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment for pulmonary tuberculosis. Br Med J. 1948;ii:769–82.Google Scholar
3
3Schulz, KF, Chalmers, I, Hayes, RJ, Altman, DG.Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–12.CrossRefGoogle ScholarPubMed
4
4The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. N Engl J Med. 1985;313:1191–200.CrossRefGoogle Scholar
5
5Sackett, DL, Hoey, J.Why randomized controlled trials fail but needn’t: a new series is launched. CMAJ. 2000 May 2;162(9): 1301–2.Google ScholarPubMed
6
6Hebert, PC, Fergusson, DA.Are we keeping research participants safe enough?CMAJ. 2010 July 13;182(10):E428.CrossRefGoogle ScholarPubMed
7
7Lehrer, J. The truth wears off. Is there something wrong with the scientific method? The New Yorker. 2010 December 13.Google Scholar
8
8Ioannidis, JP.Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005 July 13;294(2):218–28.CrossRefGoogle ScholarPubMed